Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders
July 21 2020 - 4:45PM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, today
announced that it is rescheduling the date of the Company’s Special
Meeting of Stockholders (the “Special Meeting”) previously
scheduled for Friday, June 26, 2020, to Friday, August 28, 2020, at
11:00 a.m., Eastern Time. In connection with the change of the
Special Meeting date, the record date for determining stockholders
entitled to attend and vote at the Special Meeting has been
changed to the close of business on July 15, 2020.
There are no changes to the proposals previously
described in the Company’s proxy statement for the Special Meeting.
The Company will be distributing a proxy statement, proxy card and
notice of internet availability for the Special Meeting describing
the proposals to be voted upon. Stockholders who have previously
sent in proxies, or voted by telephone or by Internet, may submit
new proxies or vote by telephone or Internet in advance of the
meeting on August 28, 2020 by one of the methods described in the
proxy statement to be distributed. If no further action is taken by
a stockholders who previously sent in a proxy, or voted by
telephone or by Internet, the stockholder’s previous elections
shall remain in effect.
To attend the Special Meeting, stockholders will
need to register at http://viewproxy.com/tonixpharma/2020vm
and enter certain information, including their name and the control
number found on the proxy card, voting instruction form, or notice
of internet availability to be distributed to stockholders, by
following the instructions available on the meeting website.
About Tonix Pharmaceuticals Holding
Corp.
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing
small molecules and biologics to treat and prevent human disease
and alleviate suffering. Tonix’s portfolio is primarily composed of
central nervous system (CNS) and immunology product candidates. The
immunology portfolio includes vaccines to prevent infectious
diseases and biologics to address immunosuppression, cancer and
autoimmune diseases. The CNS portfolio includes both small
molecules and biologics to treat pain, neurologic, psychiatric and
addiction conditions. Tonix’s lead vaccine candidate, TNX-1800*, is
a live replicating vaccine based on the horsepox viral vector
platform to protect against COVID-19, primarily by eliciting a T
cell response. Tonix expects data from animal studies of TNX-1800
in the fourth quarter of this year. TNX-801*, live horsepox virus
vaccine for percutaneous administration, is in development to
protect against smallpox and monkeypox and serves as the vector
platform on which TNX-1800 is based. Tonix is also developing
TNX-2300*, a second live replicating vaccine candidate for the
prevention of COVID-19, but using bovine parainfluenza as the
vector. Tonix’s lead CNS candidate, TNX-102 SL**, is in Phase 3
development for the management of fibromyalgia. The Company expects
results from an unblinded interim analysis in September 2020 and
topline data in the fourth quarter of 2020. TNX-102 SL is also in
development for agitation in Alzheimer’s disease and alcohol use
disorder (AUD). The agitation in Alzheimer’s disease program is
Phase 2 ready with FDA Fast Track designation, and the development
program for AUD is in the pre-Investigational New Drug (IND)
application stage. Tonix‘s programs for treating addiction
conditions also include TNX-1300* (T172R/G173Q double-mutant
cocaine esterase 200 mg, i.v. solution), which is in Phase 2
development for the treatment of life-threatening cocaine
intoxication and has FDA Breakthrough Therapy designation. TNX-601
CR** (tianeptine oxalate controlled-release tablets) is another CNS
program, currently in Phase 1 development as a daytime treatment
for depression while TNX-1900**, intranasal oxytocin, is in
development as a non-addictive treatment for migraine and
cranio-facial pain. Tonix’s preclinical pipeline includes
TNX-1600** (triple reuptake inhibitor) , a new molecular entity
being developed as a treatment for PTSD; TNX-1500* (anti-CD154), a
monoclonal antibody being developed to prevent and treat organ
transplant rejection and autoimmune conditions; and TNX-1700*
(rTFF2), a biologic being developed to treat gastric and pancreatic
cancers.
*TNX-1800, TNX-801, TNX-2300, TNX-1300, TNX-1500
and TNX-1700 are investigational new biologics and have not been
approved for any indication.
**TNX-102 SL, TNX-601 CR, TNX-1600 and TNX-1900
are investigational new drugs and have not been approved for any
indication.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(212) 688-9421
Travis Kruse (media)Russo
Partnerstravis.kruse@russopartnersllc.com(212) 845-4272
Peter Vozzo
(investors)Westwickepeter.vozzo@westwicke.com(443)
213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024